Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic ...

The Wuzhen Summit of the 2024 World Internet Conference will be held in Wuzhen, Zhejiang Province, China, from November 19 to 22. On October 24, the World Internet Conference International ...

In the period between January and September, the Indian pharmaceutical market grew by an average of 7.6%, but volume growth ...

Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken right off the store shelves, researchers found. Among 111 benzoyl peroxide (BPO ...

Primary care physicians (PCPs) play a key role in treating young patients as they progress through the "atopic march" from ...

Review notable updates that occurred in September 2024 for investigational products in development ... Phase 3 trial results Tolebrutinib (Sanofi) Bruton tyrosine kinase inhibitor Treatment of ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

Sanofi is now in “exclusive negotiations ... Some of its most popular products include the antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever Buscopan, Selsun ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella ... Shares in Tata Consumer Products, which owns brand such as Tetley, slumped nearly 7% on Monday. The ...

In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...